Tuesday, August 11, 2020

Temple University Hospital One of Five U.S. Sites Testing Rapidly-Acting Depression Drug

Hellenic News
Hellenic News
The copyrights for these articles are owned by HNA. They may not be redistributed without the permission of the owner. The opinions expressed by our authors do not necessarily reflect the opinions of HNA and its representatives.

Latest articles

On The Road to Constantinople: Repairs of Hagia Sophia Dome by 10th Century Armenian Architect

“All truths are easy to understand once they are discovered; the point is to discover them,” by Galileo di Vincenzo Bonaulti de Galilei, an Italian astronomer, physicist, and engineer.1Hagia Sophia...

Emmy-nominated TV personality Debbie Matenopoulos co-hosts ‘Home & Family’

Debbie Matenopoulos is the co-host of "Home & Family" on the Hallmark Channel. She chatted with HNA's Markos Papadatos about her show, cookbook, and...

Moving forward, with AHEPA, Brooklyn Chapter 41

Brooklyn AHEPA Chapter 41 held a monthly meeting on August 5, 2020 virtually via Zoom due to the COVID pandemic. On the agenda was...

Antonios (Tony) Malitas of Philadelphia has passed away

Malitas, Antonios (Tony) was born on January 15, 1940, in Epirus, while it was under the communistic rule of the Albanian government. Harlambos, (Harry)...

Archbishop visits Transfiguration Greek Orthodox Church During Covid-19 Pandemic

“We celebrate the first fruits of the harvest on August 6th, the Transfiguration (Metamorphosis) of Christ Feast Day,” said His Eminence, Archbishop Elpidophoros. “I...

Η Αγία Σοφία, οι Συμβολισμοί και η Τουρκία ως Καταστροφέας Πολιτισμών

Γράφει ο Ιωάννης ΜπαλτζώηςO  Τούρκος δημοσιογράφος Ραμί Τουράν σε  ένα τολμηρό του άρθρο στην εφημερίδα Σοτζιού της 14ης Ιουλίου έγραφε: «Οι οικονομικές κρίσεις και...

The destruction of civilization, the other side of the Conqueror and conquest

By Ioannis MpaltzoisThere are more mosques in Turkey than there are schools. To the existing 84,684 mosques, one more was added. Hagia Sophia became...

(Philadelphia, PA) – Current treatments for depression are often frustrating for patients. Antidepressant medications are typically slow to work, often taking four to six weeks to show results. In other patients, medications only work partially or not at all.

Temple University Hospital is one of five sites in the U.S. chosen to participate in the Rapidly-Acting Treatments for Treatment-Resistant Depression (RAPID-KOR) study – a Phase II research trial that is testing a compound which may speed therapy for severe, treatment-resistant depression. The study is funded by the National Institute of Mental Health.

“When you’re depressed, it’s not easy to wait a month or more for medication to start working,” says Mary F. Morrison, MD, MS, lead investigator of the trial at Temple and Vice Chair for Research Development for Psychiatry at the Temple University School of Medicine. “The urgent need for improved, faster-acting treatments is underscored by the fact that severe depression can be life-threatening, due to heightened risk of suicide.”

The RAPID trial is testing a compound known as CERC-501 (an investigational medication) that is taken orally for six days. CERC-501 is a selective kappa opioid receptor antagonist, which means it acts upon the endogenous opiate system in the regions of the brain that are involved in stress and depression.

“The exact mechanisms of why CERC-501 might relieve symptoms of depression are not known, but chronic stress increases dynorphin, part of the kappa opiate system, and dynorphin can cause low mood,” says Dr. Morrison.

Thanks for reading Hellenic News of America

During the trial, patients take CERC-501 for six days. Their symptoms are assessed each day while on the compound and then during follow-up visits that end 14 days after the last dose. Patients continue on their current antidepressants during the trial.

“This compound is not a cure for all depression, but the hope is that it can act as a ‘booster’ for patients, giving them fast-acting relief of their depressive symptoms and augment the action of their initial antidepressant,” says Dr. Morrison. “Through this research, we hope to enhance our understanding of the underlying mechanisms of depression and guide the development of new ways to quickly help patients who have not responded to current antidepressant medications.”

Temple is currently pre-screening patients for the trial. Interested individuals may call Jennifer Henry at 215-707-8204 or email her at [email protected] for more information.


The copyrights for these articles are owned by the Hellenic News of America. They may not be redistributed without the permission of the owner. The opinions expressed by our authors do not necessarily reflect the opinions of the Hellenic News of America and its representatives.